DICE Therapeutics, Inc.
(NASDAQ GM: DICE)
Rigrodsky Law, P.A. is investigating DICE Therapeutics, Inc. (“DICE”) regarding possible breaches of fiduciary duties and other violations of law related to DICE’s agreement to be acquired by Eli Lilly and Company. Under the terms of the agreement, DICE shareholders will receive $48.00 per share in cash.